Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02977533 (ClinicalTrials.gov)	December 1, 2016	28/11/2016	A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: GZ402668;Drug: Placebo;Drug: Acyclovir	Sanofi	NULL	Completed	18 Years	65 Years	All	20	Phase 1	Germany
2	NCT02282826 (ClinicalTrials.gov)	October 2014	31/10/2014	A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: GZ402668;Drug: placebo;Drug: acyclovir	Genzyme, a Sanofi Company	NULL	Completed	18 Years	65 Years	Both	48	Phase 1	Germany